Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?

The article favors Fidelity MSCI Health Care Index ETF (FHLC) as a lower-cost, diversified foundation: its 0.08% expense ratio compares with 0.59% for Invesco Biotechnology & Genome ETF (PBE). Over five years, $1,000 grew to $1,383 in FHLC versus $1,352 in PBE, while maximum drawdowns were 17.7% and 32.6%, respectively. PBE had the higher trailing one-year return as of October 5, 2026 (35.6% vs. 18.7%) and a slightly higher yield (1.4% vs. 1.2%), but is more concentrated in biotech.

Analysis

The key portfolio implication is not simply “cheap versus expensive”: the funds package different sources of healthcare risk. FHLC’s low fee is a persistent relative advantage, but its broad label can obscure meaningful mega-cap exposure—LLY alone is a large position—so it may participate in GLP-1 enthusiasm without offering broad participation in smaller innovation names. PBE is more exposed to company-specific clinical, regulatory, and financing outcomes; acquisition activity can create sharp upside in individual holdings, but deal premiums are episodic and do not remove the risk of failed trials or delayed commercialization.

The five-year comparison suggests PBE’s additional volatility has not translated into better cumulative returns over that window. That supports a cautious relative-value tilt, not a claim that biotech is structurally unattractive: one strong clinical or M&A cycle could reverse relative performance quickly. In the next 1–3 months, biotech readouts, deal announcements, and changes in risk appetite are the likely swing factors; over 6–18 months, sustained drug launches and clinical pipeline conversion matter more than ETF-level fee differences. Verify current holdings, bid-ask spreads, and performance through different market regimes before sizing; the supplied snapshot alone does not establish valuation or future returns.

Key Decisions for Investors

• For a core healthcare allocation, favor FHLC over PBE on fee efficiency and lower historical drawdown, while recognizing its large-cap concentration and LLY exposure. Treat this as a relative-risk choice, not a low-risk trade.
• A measured relative-value expression is long FHLC versus underweight PBE, preferably built in stages rather than chasing after biotech rallies. Reassess if PBE begins delivering sustained relative outperformance alongside improving clinical or commercial evidence.
• Keep PBE as a satellite only where there is explicit conviction in biotech/genomics catalysts. Its holdings, including Natera, Illumina, and Biogen, expose investors to distinct company-specific event paths that a sector-level thesis may not capture.
• Falsifiers and alerts: a material shift in relative performance, changes in index composition or concentration, unusually wide PBE trading spreads, major clinical/regulatory setbacks, or sustained biotech deal activity and pipeline execution that broaden sector gains beyond a few names.